Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

by @JTC_PALIdev | Jul 5, 2023 | Press Releases

Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the...

Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

by @JTC_PALIdev | Jun 14, 2023 | Press Releases

Live webcast fireside chat on Thursday, June 22nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 — Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D....

Palisade Bio Promotes J.D. Finley to Chief Executive Officer

by @JTC_PALIdev | Jun 1, 2023 | Press Releases

Carlsbad, CA, June 01, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley has...

Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts

by @JTC_PALIdev | May 24, 2023 | Press Releases

Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose optimization study with 25% enrollment complete Carlsbad, CA, May 24, 2023 — Palisade Bio, Inc. (Nasdaq: PALI)...

Palisade Bio Reports First Quarter 2023 Financial Results

by @JTC_PALIdev | May 12, 2023 | Press Releases

Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic...